Interleukin-17F Has Anti-Tumor Effects in Oral Tongue Cancer

Cancers

EhsanulHoque Apu¹  MauricioRocha Dourado²  Abdelhakim Salem³  Sakhr Murshid³  Rabeia Almahmoudi³  Ahmed Al-Samadi³  Tuula Salo³ 

[1] Department of Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI 48824, USA;Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Campinas-SP, Piracicaba, São Paulo 13083-970, Brazil;Department of Oral and Maxillofacial Diseases, University of Helsinki, Biomedicum Helsinki 1, 00014 Helsinki, Finland;

关键词: interleukin-17F;    cancer immunotherapy;    cytokine therapy;    tongue cancer;    oral squamous cell carcinoma;    proliferation;    invasion;    apoptosis;    angiogenesis;    HUVEC cells;   

DOI  :  10.3390/cancers11050650

来源: DOAJ

【 摘 要 】

We recently showed that extracellular interleukin-17F (IL-17F) correlates with better disease-specific survival in oral tongue squamous cell carcinoma (OTSCC) patients. However, the underlying mechanisms of such effect remain obscure. Here, we used qRT-PCR to assess the expression of IL-17F and its receptors (IL-17RA and IL-17RC) in two OTSCC cell lines (HSC-3 and SCC-25) and in normal human oral keratinocytes (HOKs). IL-17F effects on cancer cell proliferation, migration, and invasion were studied using a live-imaging IncuCyte system, and a Caspase-3/7 reagent was used for testing apoptosis. 3D tumor spheroids were utilized to assess the impact of IL-17F on invasion with or without cancer-associated fibroblasts (CAFs). Tube-formation assays were used to examine the effects of IL-17F on angiogenesis using human umbilical vein endothelial cells (HUVEC). OTSCC cells express low levels of IL-17F, IL-17RA, and IL-17RC mRNA compared with HOKs. IL-17F inhibited cell proliferation and random migration of highly invasive HSC-3 cells. CAFs promoted OTSCC invasion in tumor spheroids, whereas IL-17F eliminated such effect. IL-17F suppressed HUVEC tube formation in a dose-dependent manner. Collectively, we suggest that IL-17F counteracts the pro-tumorigenic activity in OTSCC. Due to its downregulation in tumor cells and inhibitory activity in in vitro cancer models, targeting IL-17F or its regulatory pathways could lead to promising immunotherapeutic strategies against OTSCC.

【 授权许可】

Unknown